Added to YB: 2026-02-09
Pitch date: 2026-02-05
NVO [neutral]
Novo Nordisk A/S
+8.95%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 282.15
Price Target
N/A
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
value
Novo Nordisk, is the worst yet to come?
NVO (update): Danish pharma giant faces first decline in 20yrs as Trump's 'Most Favored Nation' slashes Ozempic/Wegovy prices 70% to $299/mo. Lost market share below 50% vs Eli Lilly's Zepbound. 2026 sales/profit -5% to -13% guidance vs market expectations. Trades 15x P/E (60% drop). Oral Wegovy launch successful but margin pressured. Medicare coverage mid-2026 upside potential.
Read full article (8 min)